Sahar J. Alothman, US Medical Director | Breast Cancer at AstraZeneca, shared a post on LinkedIn:
“I’ll be at ASCO2026 in Chicago this week.
Breast cancer data at this meeting has the potential to change lives – not just in the abstracts, but for real patients making real treatment decisions in the months ahead. That’s what makes this meeting matter.
The progress we’re seeing in biomarker-driven therapy, treatment sequencing, and long-term survivorship is extraordinary. But progress only translates to impact when the right people are aligned around it.
If you’re at ASCO, whether you’re in research, clinical practice, policy or other, I’d welcome the chance to connect.
Drop a comment, or reach out directly. See you in Chicago!”
Other articles on OncoDaily.